Experiences of the Data Monitoring Committee for the RECOVERY trial, a large-scale adaptive platform randomised trial of treatments for patients hospitalised with COVID-19
ConclusionsRECOVERY ’s streamlined adaptive platform design, linked to hospital-level and population-level health data, enabled the rapid and reliable assessment of multiple treatments for hospitalised patients with COVID-19. The later introduction of factorial assessments increased the trial’s efficiency, without compromising the DMC’s ability to assess safety and efficacy. Requests for the release of unblinded primary outcome data to regulators at points when data were not mature required significant efforts in communication with the regulators by the DMC to avoid inappropriate early trial termination. (Source: Trials)
Source: Trials - October 18, 2022 Category: Research Source Type: clinical trials

Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
Conditions:   Stage IV Colorectal Cancer Positive for BRAF V600E Mutation;   Colorectal Cancer;   Colorectal Cancer Stage IV Intervention:   Drug: Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab Sponsors:   Northwestern University;   National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 13, 2022 Category: Research Source Type: clinical trials